Phylex BioSciences
Phylex Biosciences is a next-generation vaccine company located at the crossroads of artificial intelligence and immunology. They develop innovative mRNA nanoparticle vaccines using advanced computational analysis and deep learning AI systems, targeting pathogens such as SARS-CoV-2 and Nipah virus. Their vaccines aim to provide long-lasting immunity, counter immune imprinting, and protect against viral dissemination and neurological symptoms.
Industries
Nr. of Employees
small (1-50)
Phylex BioSciences
Del Mar, California, United States, North America
Products
SARS-CoV-2 mRNA nanoparticle vaccine candidate
mRNA vaccine candidate encoding self-assembling nanoparticles displaying SARS-CoV-2 antigen(s), designed to broaden immunity against variants and address immune imprinting.
Nipah virus mRNA nanoparticle vaccine candidate
mRNA vaccine candidate encoding self-assembling nanoparticles presenting Nipah virus antigen(s), developed to induce protective immune responses against Nipah virus.
SARS-CoV-2 mRNA nanoparticle vaccine candidate
mRNA vaccine candidate encoding self-assembling nanoparticles displaying SARS-CoV-2 antigen(s), designed to broaden immunity against variants and address immune imprinting.
Nipah virus mRNA nanoparticle vaccine candidate
mRNA vaccine candidate encoding self-assembling nanoparticles presenting Nipah virus antigen(s), developed to induce protective immune responses against Nipah virus.
Expertise Areas
- mRNA vaccine development
- Nanoparticle-based antigen display
- Computational vaccine design and AI
- Vaccine formulation and thermostability engineering
Key Technologies
- mRNA vaccine technology
- Self-assembling nanoparticle platforms
- Deep learning and AI for immunogen design
- Thermostable vaccine formulation